Discovery Metabolomics & Lipidomics Fact Sheet

At Sapient, we believe that drugs can be developed much faster, cheaper, and more effectively through biomarker-driven drug discovery. We also believe extensive biomarker insights lie beyond the genome, in dynamic metabolites and lipids that read-out health, disease, and drug response over time.

That is why we have developed technologies and approaches to enable rapid, broad profiling of these small molecule chemistries, enabling discovery metabolomics and lipidomics at an entirely new speed and scale.

Learn how our rapid liquid chromatography-mass spectrometry (rLC-MS allow us to measure >15,000 metabolites and lipids per biosample, across thousands of samples at a time. Learn how our expansive metabolite standard library, comprising more than 13,000 reference standards, enables us to maximize definitive metabolite identifications in each study and elucidate putative structural insights for those molecules that are still unknown.

Using these innovative approaches, Sapient has built an in-house database – our DynamiQ™ Insights Engine – in which we have longitudinally collected thousands of metabolite, lipid, protein, and cytokine measures across >62,000 human bisoamples linked to real-world data. We can use this deeply phenotyped database to confirm your biomarker findings in independent populations and further explore biomarker-disease and biomarker-phenotype associations.